When “Brady the Brave” was born, his parents, Chris and Eileen, were shocked to learn that his feet were raw and missing skin. After two weeks in the NICU, Brady was diagnosed with Recessive Dystrophic Epidermolysis Bullosa (RDEB), meaning that Brady’s skin, his body’s largest organ, was so fragile that it would come off his body with the slightest touch. Simple scrapes became severe wounds, daily wrapping in full body bandages was required, and routine tasks like eating, walking, and sleeping became monumental daily challenges. Yet Brady, now two years old, has an indomitable spirit. He is a fighter, and so are his parents.

“Our family keeps high hopes that Brady will be able to do most of the things that ‘normal’ children can do. EB Research Partnership is working diligently to fund the research and the clinical trials needed to improve Brady’s quality of life and give him the chance to ‘be a kid.’ Treatment would mean Brady could walk and possibly even run! We will not give up and we are grateful for all who believe that together we will heal EB.” – Eileen

At EB Research Partnership, we stand with Brady and all those battling EB. Thanks to your support, we are pursuing our mission to rapidly accelerate treatments and cures for EB and, in the process, pioneering a new venture philanthropy model for how rare diseases can be cured.

Since 2010, we have raised over $25 million to treat and cure EB. We have partnered with brilliant researchers and doctors, assembled a world-class scientific advisory board, created a collaborative medical research consortium and shared dataset among 21 institutions, and funded a research portfolio of more than 50 projects. EBRP supports research spanning all forms and approaches of healing EB, including exon skipping and gene therapy. When we started in 2010, there were only two clinical trials for EB. Today, there are nearly 20. While our goal is to cure EB, the research we support has the potential to help treat or cure the estimated 7,000 rare diseases that impact 10% of the global population.

After years of hard work, we have reached the threshold of a far more promising future for children born with EB. Leading researchers believe that both a cure and life-changing treatments are within reach. To make this belief a reality, we need to accelerate our efforts. In the next three years, we aim to double our efforts, raising $25 million in half the time to maximize the possibility of success for those living today with EB. While this task is daunting, we believe that it can be done. Because if not us, then who? If not now, then when? The time to act is today, and the responsibility is ours. Together we can partner to make our vision of an EB-free world a reality.

We thank you for joining us in this journey and provide this Impact Report as a way to show you the meaningful difference your support has made on accelerating the path to healing EB.

Sincerely,

Michael Hund
Executive Director
EB Research Partnership

Alexander Silver
Chairman
EB Research Partnership
Founded in 2010, EB Research Partnership (EBRP) is the largest 501(c)(3) nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa (EB), a group of devastating and life-threatening skin disorders that affect children from birth. EBRP works to treat and cure EB as quickly and efficiently as possible and fulfills our mission by partnering with non-profit and for-profit organizations, foundations, individual donors, and the EB and research communities.

EB Research Partnership utilizes an innovative venture philanthropy model, leveraging concepts from principal investing and applying them toward achieving philanthropic goals. When making a grant to a research project, EBRP retains the added upside of generating a recurring donation stream if the therapy or product is commercially successful; then, EBRP can use this revenue to fund additional research.

partner with us in our mission to further life-saving research for EB
EBRP reviews grant applications biannually and awards funding to competitive and innovative research projects with the potential to lead to commercially feasible products and therapies to treat and cure EB. The applications are evaluated and scored by EBRP’s Scientific Advisory Board (SAB), which is made up of experts in various research and clinical fields and which recommends the best projects for funding. In 2017, EBRP awarded grants to 11 new projects totaling $2,746,094 — securing matching funds in partnership with the EB Medical Research Foundation and Cure EB.

## 2017 Newly Funded Projects

<table>
<thead>
<tr>
<th>INSTITUTION</th>
<th>PROJECT NAME</th>
<th>PRINCIPAL INVESTIGATOR(S)</th>
<th>AMOUNT AWARDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Southern California</td>
<td>An Evaluation of the Feasibility of Aminoglycosides to Induce Premature Termination Codon Read-through and Restore Functional Laminin 332 in Nonsense Mutations Associated with H-JEB</td>
<td>Mei Chen, PhD, David Woodley, MD</td>
<td>$178,500</td>
</tr>
<tr>
<td>Stanford University, University of Colorado, and Columbia University</td>
<td>Epidermolysis Bullosa (EB) iPS Cell Consortium</td>
<td>Anthony E. Oro MD/PhD, Dennis Roop PhD, Angela Christiano PhD</td>
<td>$842,333</td>
</tr>
<tr>
<td>Stanford University</td>
<td>Computational Drug Repurposing for Epidermolysis Bullosa Simplex</td>
<td>Andrew A. Radin, Joyce Teng, MD, PhD</td>
<td>$127,310</td>
</tr>
<tr>
<td>University of Colorado</td>
<td>iPS Cell Biobank for EB Patients</td>
<td>Dennis Roop, PhD</td>
<td>$83,790</td>
</tr>
<tr>
<td>Pediatric Dermatology Research Alliance</td>
<td>Stigma, Anxiety, and Depression in Children and Adolescents with Skin Disorders</td>
<td>Amy Paller, MD, Sarah Chamlin, MD</td>
<td>$10,000</td>
</tr>
<tr>
<td>Thomas Jefferson University</td>
<td>Targeting APOBEC for RDEB SCC Prevention</td>
<td>Andrew South, PhD</td>
<td>$349,089</td>
</tr>
<tr>
<td>Tufts University</td>
<td>National Epidermolysis Bullosa Eye Disease Survey</td>
<td>Vicki Chen, MD</td>
<td>$38,325</td>
</tr>
<tr>
<td>University of California, San Francisco and Thomas Jefferson University</td>
<td>Deep Sequencing Diagnostic Field Lesions in Recessive Dystrophic Epidermolysis Bullosa Squamous Cell Carcinoma</td>
<td>Raymond Cho, MD, Andrew South, PhD</td>
<td>$200,000</td>
</tr>
<tr>
<td>Stanford University and Krystal Biotech</td>
<td>Engineered COL7A1- HSV-1, KB103 Applied Intradermally/Topically as a Treatment for Recessive Dystrophic Epidermolysis Bullosa</td>
<td>Peter Marinkovich, MD</td>
<td>$770,000</td>
</tr>
<tr>
<td>Tel Aviv Sourasky Medical Center</td>
<td>Improving Wound Healing in Epidermolysis Bullosa Through Modulation of the Skin Microbiome</td>
<td>Eli Sprecher, MD</td>
<td>$85,000</td>
</tr>
<tr>
<td>University of Freiburg</td>
<td>Perturbed Proteolytic Activation by Kallikrein Family-Proteases in Recessive Dystrophic Epidermolysis Bullosa: New Prospects for Therapies</td>
<td>Dimitra Kiritsi, MD, Alexander Nystrom, PhD, Georgia Sotropoulou, PhD</td>
<td>$61,747</td>
</tr>
<tr>
<td><strong>TOTAL AWARDED</strong></td>
<td></td>
<td></td>
<td><strong>$2,746,094</strong></td>
</tr>
</tbody>
</table>
### 2017 Ongoing Project Funding

<table>
<thead>
<tr>
<th>INSTITUTION</th>
<th>PROJECT NAME</th>
<th>PRINCIPAL INVESTIGATOR(S)</th>
<th>AMOUNT FUNDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Minnesota</td>
<td>Gene Editing of Type VII Collagen Mutations</td>
<td>Jakub Tolar, MD, PhD</td>
<td>$279,667</td>
</tr>
<tr>
<td>Seattle Children’s Hospital</td>
<td>Development of a Foamy Viral Vector to Express Col7A1</td>
<td>Andrew Scharenberg, MD</td>
<td>$67,487</td>
</tr>
<tr>
<td>Stanford University and Immusoft Corporation</td>
<td>Cell Reprogramming of Autologous Cells as Treatment Strategies for RDEB</td>
<td>Peter Marinkovich, MD, Jean Tang, MD, PhD, Eric Herbig, PhD, Scott McIvor, PhD</td>
<td>$253,781</td>
</tr>
<tr>
<td>Stanford University</td>
<td>Phase 1 Clinical Trial of Injected C7 Protein vs Placebo for Wound Healing in five RDEB Subjects</td>
<td>Jean Tang, MD</td>
<td>$181,376</td>
</tr>
<tr>
<td>Stanford University and Corium International</td>
<td>C7 Protein Therapy for Microneedles</td>
<td>Jean Tang, MD</td>
<td>$167,525</td>
</tr>
<tr>
<td>University of Colorado</td>
<td>R01 Match for Induced Pluripotent Stem Cell Research</td>
<td>Dennis Roop, PhD</td>
<td>$142,970</td>
</tr>
<tr>
<td>Stanford University</td>
<td>EB Therapeutic Reprogramming of iPS Cells</td>
<td>Anthony E. Oro MD/PhD</td>
<td>$40,000</td>
</tr>
<tr>
<td>Thomas Jefferson University</td>
<td>Targeting Fibrosis for RDEB Therapy</td>
<td>Andrew South, PhD</td>
<td>$147,848</td>
</tr>
<tr>
<td>Stanford University</td>
<td>Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients with Epidermolysis Bullosa</td>
<td>Jean Tang, MD</td>
<td>$52,318</td>
</tr>
<tr>
<td>Stanford University</td>
<td>Suction Blister Device and Tissue Analytics</td>
<td>Jean Tang, MD</td>
<td>$42,275</td>
</tr>
<tr>
<td>Stanford University</td>
<td>Laminin-332 Protein Therapy For Junctional Epidermolysis Bullosa</td>
<td>Jean Tang, MD</td>
<td>$36,686</td>
</tr>
<tr>
<td>University of Minnesota</td>
<td>Gene Editing Robot</td>
<td>Jakub Tolar, MD, PhD</td>
<td>$247,191</td>
</tr>
</tbody>
</table>

**TOTAL FUNDED** 1,659,124
In the first grant cycle of 2018, EBRP awarded $5,758,529.86 for innovative research, more than double the amount awarded in the previous year. EBRP anticipates that this number will increase further as applications for the second grants cycle are reviewed. EBRP continues to develop the research landscape, producing an upward trend in the number of applications received and projects funded.

**Grant Awards are up 183% Over Last Year!**

<table>
<thead>
<tr>
<th>INSTITUTION</th>
<th>PROJECT NAME</th>
<th>PRINCIPAL INVESTIGATOR(S)</th>
<th>AMOUNT AWARDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stanford University</td>
<td>Bridge Funding for R01 Application to Optimize the Manufacturing of Genetically Corrected, Induced Pluripotent Cell-Derived Epithelial Sheets for Definitive Treatment of Dystrophic Epidermolysis Bullosa</td>
<td>Anthony Oro, MD, PhD</td>
<td>$258,447</td>
</tr>
<tr>
<td>University of Southern California</td>
<td>A Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients with Nonsense Mutations After Topical and Intravenous Gentamicin Treatment</td>
<td>Mei Chen, PhD, David Woodley, MD</td>
<td>$254,100</td>
</tr>
<tr>
<td>The Hospital for Sick Children</td>
<td>A Double-Blind, Randomized, Crossover, Multi-Center, Feasibility Trial of Pregabalin for the Treatment of RDEB-Associated Neuropathic Pain and Itch.</td>
<td>Elena Pope, MD, MSc, Margarita Calvo, MD, MSc, PhD, Irene Lara-Correas, MD, MSc</td>
<td>$179,977</td>
</tr>
<tr>
<td>Columbia University Medical Center</td>
<td>Conform-a-Care is a Tubular, Elasticated, Multilayered Wound Dressing that Contours to the Body, Providing Optimal Wound Care.</td>
<td>Laura Levin, MD</td>
<td>$33,500</td>
</tr>
<tr>
<td>Universite Laval Research Center</td>
<td>Feasibility Study on the Production of Skin Substitutes from Revertant Gene Corrected Cells from DEB Patients.</td>
<td>Lucie Germain, PhD, Elena Pope, MD, MSc, Manuel Caruso, PhD</td>
<td>$197,505</td>
</tr>
<tr>
<td>University of Minnesota</td>
<td>Next Generation Genome Editing for RDEB.</td>
<td>Jakub Tolar, MD, PhD</td>
<td>$1,000,000</td>
</tr>
<tr>
<td>ProQR Therapeutics</td>
<td>Clinical Development of QR-313 for Treatment of DEB</td>
<td>David Rodman, MD</td>
<td>$5,000,000</td>
</tr>
<tr>
<td><strong>TOTAL AWARDED</strong></td>
<td></td>
<td></td>
<td><strong>$7,758,529</strong></td>
</tr>
</tbody>
</table>

**2018 First Half Newly Funded Projects**

[Graph showing Grant Awards are up 183% Over Last Year!]

EB Research Partnership Impact Report 2017 // ebresearch.org // 9
Highlighted Projects: 2018 First Half

ProQR Therapeutics: Clinical Development of QR-313 for Treatment of DEB

This grant marks the largest EBRP-funded clinical trial with human participants. ProQR is conducting a clinical trial of QR-313, a drug candidate that causes skipping of exon 73 in collagen VII protein synthesis. The exon-skipping technique excludes the problematic exon from the final protein product, allowing the protein to function properly. A subset of RDEB patients’ disease-causing mutation lies within exon 73 in collagen VII.

University of Southern California: An Evaluation of the Feasibility of Aminoglycosides to Induce Premature Termination Codon Read-through and Restore Functional Laminin 332 in Nonsense Mutations Associated with H-JEB

EBRP granted funds to Dr. Mei Chen and Dr. David Woodley to study whether aminoglycosides, a class of antibiotics, can induce the read-through of nonsense mutations in Laminin 332 that cause Junctional EB. Nonsense mutations direct cells to prematurely stop protein synthesis, leading to the production of a shortened and nonfunctional protein. Aminoglycosides can direct the cell to skip over that stop signal, restoring the production of the full-length protein. EBRP also funded a similar study conducted by these doctors on the aminoglycoside Gentamicin and its effect on nonsense mutations in collagen VII, the protein affected in Recessive Dystrophic EB.
Along with leading North American pediatric dermatologists, EBRP founded the Epidermolysis Bullosa Clinical Research Consortium (EBCRC), a collaborative research group that conducts high-quality clinical and translational research aimed at improving and advancing care for EB patients. The EBCRC, led by Dr. Anna Bruckner at Children’s Hospital Colorado, has grown to include 21 prominent medical centers. Each EBCRC site contributes patient data to the EB Clinical Characterization and Outcomes Database (CCOD), which has more than 700 patients enrolled. EBRP aims to accumulate the largest data set in EB to uncover a deeper understanding of the biology of the disease and to reveal greater insights into how it can be treated. EBRP has provided over $600,000 in funds to EBCRC sites to date.

2017 Funding: $91,983
In 2016, EBRP founded the EB iPS Cell Consortium, consisting of research teams led by Dr. Angela Christiano from Columbia University Medical Center, Dr. Anthony Oro from Stanford University School of Medicine, and Dr. Dennis Roop from the University of Colorado Anschutz Medical Campus, to foster collaboration among leading scientists in hopes of accelerating the path to treatments and cures. The consortium studies cutting-edge induced pluripotent stem (iPS) cell technology and its application as a potentially curative therapy for EB. These iPS cells are normal adult cells that are reprogrammed to act as stem cells, allowing the possibility for patients to produce their own unlimited supply of stem cells for use in life-saving therapies. The EB iPS Cell Consortium has already established a protocol for manufacturing autologous CRISPR-corrected, iPS-derived keratinocyte sheets for grafting. This technology is at the forefront of medical research, and the consortium has received additional multi-million dollar grants from highly regarded institutions, such as the California Institute of Regenerative Medicine (CIRM).
Interviewing Tony Oro, MD

Q | What is the potential impact of the iPS Cell Consortium for patients with EB and also other rare diseases?

The iPS Cell Consortium represents a talented group of EB researchers with complementary skills to transform a promising new technology into a therapeutic reality for patients with EB. As we know, iPS cells are derived from an individual’s own cells and possess the ability to be genetically corrected and manufactured into tissue stem cells to replace a patient’s defective ones. Previously performed experiments have shown that one dose of corrected skin stem cells can close wounds for many years, raising the possibility of “definitive” therapy. Also, iPS cells allow large numbers of corrected skin stem cells to be produced. While the goal of the consortium is to produce a safe and robust manufacturing method for EB patients, the same method might also be used in the future to manufacture other tissue stem cells to help patients with other rare or common diseases.

Q | Why is collaboration so important in medical research?

Medical researchers are like blind men/women touching different parts of the elephant. Most of the time, we only get part of the picture, or, as individuals, have the resources to develop only a portion of a therapy very slowly. A collaborative and complementary research team can “touch” many parts of the elephant simultaneously, grasping a larger part of the whole picture. Team members bring resources and talents that will help researchers overcome stumbling blocks and accelerate therapy development.

“Our work in skin and stem cell biology has opened up therapeutic avenues we never thought possible.”

— Tony Oro, MD

Q | What inspired you to focus on research for patients with EB?

I completed my dermatology clinical training at Stanford University, where we have a clinic focused on patients and their families suffering from EB. Watching heroic RDEB patients navigate life despite the suffering inspires a researcher to find ways to help them. Our work in skin and stem cell biology has opened up therapeutic avenues we never thought possible. Our patients and their families have given so much to us; ultimately, we hope our work will give back to the EB community.
When EBRP was founded in 2010, only two clinical trials were underway for potential EB therapies. Today, more than 20 such trials are ongoing. EBRP’s funding of innovative research over the last four years has directly impacted the EB clinical landscape.

Highlighted Clinical Trials

**Abeona Therapeutics and Stanford University:** Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics and Stanford University are working with the FDA to commence a pivotal Phase 3 clinical trial of EB-101, their cell-therapy product for the treatment of RDEB, as of late 2018. EB-101 is a skin graft made from a patient’s own cells that have been genetically corrected to produce collagen VII protein. In May, results from the completed Phase 1/2 clinical trial confirmed that EB-101 is safe and well-tolerated, established anchoring fibrils, and significantly healed treated wounds, with >50% closure two years post administration. This trial will be the first to reach Phase 3 for an EB therapy, marking significant progress in the EB research community.

**Castle Creek Pharmaceuticals, LLC:** Safety and Efficacy of Diacerein 1% Ointment Topical Formulation Compared to Placebo for Subjects with Epidermolysis Bullosa Simplex (EBS)

In the Phase 2/3 DELIVERS study, researchers are testing the safety and efficacy of CCP-020, Castle Creek’s topical treatment for EBS. CCP-020 is a diacerein 1% ointment with the potential to block an inflammatory pathway, which may promote healing in EBS patients. EBS is the most prevalent subtype of EB, so progress in this field will impact a significant number of those living with EB.

**Fibrocell Science, Inc.:** A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

In May, Fibrocell Science announced positive interim results on their Phase 1/2 clinical trial of FCX-007, a gene therapy candidate for the treatment of RDEB. The therapy involves injections of patients’ cells that have been genetically modified to produce collagen VII into wounded areas. FCX-007 was well-tolerated and promoted wound healing in patients, marked by the presence of collagen VII and anchoring fibrils, up to 52 weeks post administration. Fibrocell is currently enrolling patients for Phase 2 of this trial.
Food & Drug Administration

In April, EBRP Senior Accountant and EB Advocate, Michelle Hall, sat on the panel of an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting with the Food and Drug Administration (FDA) to provide her unique perspective. Along with others affected by EB, Michelle helped lead a discussion on living with the disorder and what constitutes meaningful treatment. The information shared by the panel and the data collected at the meeting will be considered in the FDA’s risk-benefit analyses for potential EB therapies. In addition, academic researchers and the regulated drug industry may consider this data when designing clinical trials for their products. Collaboration between the FDA and the EB research and patient communities is critical to furthering progress in our mission to find treatments and cures. In response to the data collected at the meeting, the FDA released guidance for the industry on drug development in EB.

“Sharing patients’ perspectives with regulatory agencies like the FDA is crucial to speed up the approval process and make life-changing therapies available to the EB community.” — Michelle Hall

Department of Defense

The United States Department of Defense (DoD) granted $9.3 million to EB researchers for the next five years through their Peer Reviewed Medical Research Program (PRMRP). Despite making up less than 0.5% of the program applicants, EB researchers comprised 5% of the grant winners. Additionally, 67% of EB research applicants received awards, gaining a higher acceptance level than in any other disease group. EBRP-backed scientists Dr. Dennis Roop of the University of Colorado Anschutz and Dr. Andrew South of Thomas Jefferson University were awarded more than $5 million of this funding. Dr. Roop will receive $3.8 million to continue studies on potential stem cell treatments for chronic skin wounds, and Dr. South will receive $1.7 million for his work on squamous cell carcinoma in EB patients. The DoD’s funding of these projects proves the merit of EBRP’s SAB in determining the most innovative research to fund.
events
In 2017 $1,902,288 was raised through EBRP’s annual events and by community-led events held throughout the country by driven supporters of EBRP and the EB community.

2017–18 EBRP Events

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>All In For A Cure</td>
<td>May 11, 2017</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Night of Discovery</td>
<td>Sept. 23, 2017</td>
<td>Long Beach, CA</td>
</tr>
<tr>
<td>ACTion for Jackson</td>
<td>Nov. 8, 2017</td>
<td>New York, NY</td>
</tr>
<tr>
<td>All In For A Cure</td>
<td>May 16, 2018</td>
<td>New York, NY</td>
</tr>
</tbody>
</table>

2017–18 Community-Led Events

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change for Charley</td>
<td>Nov. 11, 2017</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>Pursuit for Patterson</td>
<td>Nov. 11, 2017</td>
<td>Seattle, WA</td>
</tr>
<tr>
<td>Evening at Malibu Farm</td>
<td>Dec. 14, 2017</td>
<td>Miami Beach, FL</td>
</tr>
<tr>
<td>Bobby Kaps Jump for EB</td>
<td>Jan. 1, 2018</td>
<td>Southport, CT</td>
</tr>
<tr>
<td>Plunge for Elodie</td>
<td>March 3, 2018</td>
<td>Hingham, MA</td>
</tr>
<tr>
<td>Believe in Brady</td>
<td>April 18, 2018</td>
<td>Houston, TX</td>
</tr>
</tbody>
</table>

Upcoming Events | Save the Date!

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Night of Discovery</td>
<td>Oct. 6, 2018</td>
<td>Long Beach, CA</td>
</tr>
<tr>
<td>ACTion for Jackson</td>
<td>Nov. 8, 2018</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Plunge for Elodie</td>
<td>March 2, 2019</td>
<td>Wellesley, MA</td>
</tr>
<tr>
<td>Change for Charley</td>
<td>March 9, 2019</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>Believe in Brady</td>
<td>April 7, 2019</td>
<td>Houston, TX</td>
</tr>
</tbody>
</table>
The eighth annual ACTion for Jackson gala was a record-breaking success! More than 700 supporters gathered at 583 Park Avenue and raised nearly $1.3 million to accelerate EB research. Michael and Nell Valentine graciously shared a video of their son Gabe, a young boy with EB who passed away in June 2017, and Michael gave an inspiring speech to pass on his son's final wish — to find a cure for EB. Within minutes, the room rallied to fully fund the evening’s special project, a gene-editing robot in honor of Gabe for Dr. Jakub Tolar's lab at the University of Minnesota. We greatly appreciate all the generous sponsors, donors, and friends who came together to make the event such a success.
Plunge for Elodie
March 3, 2018
Hingham, MA

The first annual Plunge for Elodie was organized by a group of women in support of their lifelong friend, EBRP Board Member Emily Kubik, whose two-year-old daughter Elodie lives with RDEB. Despite harsh weather conditions, supporters plunged into frigid winter waters and raised $150,000 for EBRP. Actress Jessica Biel joined the action by taking the plunge remotely and posting a video on her social media channels, sparking viewers to virtually join the fun and plunge into pools, tubs, and even the snow!
EBRP is committed to the highest financial responsibility, directing 90% of revenue to research and related programming. For complete audited financials, please visit our website at www.ebresearch.org.

**2017 EBRP Support & Revenue**

- Contributions $1,428,927
- Fundraising Events $1,902,288
- Venture Investments $3,075,590
- In-kind Contributions $198,108

**2017 EBRP Spending Allocation**

- Program & Research $1,866,523
- Management $330,004
- Fundraising $313,625
- Designated Research Funding $4,094,761

**Ending Net Assets:** $12,018,774
statistics
500,000 People are estimated to have EB worldwide.

1 in 30,000 People are estimated to be affected by EB.

50 Research Projects funded since inception.

25 Concurrent Research Projects funded today.

10x the Clinical Trials
In 2010, there were two. Today there are 20.

$25 Million raised since EBRP’s inception.

7,000 Rare Diseases impacting 10% of the global population that our model can impact.
Board of Directors

Alexander Silver  
Chairman & Co-Founder

Jill Vedder  
Vice Chair & Co-Founder

Ed Vedder  
Co-Founder

Jamie Silver  
Co-Founder

Heather Fullmer  
Co-Founder

Eileen Attar  

Tracy Baldwin  

Jeffrey Berger  

Mark Bomback  

Chad Ceretto  

Eleanor Dehoney  

Ari Deshe  

Daniel Deshe  

Faye Dilgen  

Stephen Evans

Edward Grossmann

Richard Grossmann

Matthew Holmes

Michael Kahn

Emily Kubik

Jennifer Kauf

Kate Lee

Alexander Lemos

Abbie Levine

Elizabeth Morano

Joshua Paulson

Matthew Prince

Whitney Pollack

Margaret Silver

Monique Sock

Jared Stern

Nicole Vandenberg

Rob Veres

Scientific Advisory Board

Anne Lucky, MD,  
Scientific Advisory Board Chair

Richard Azizkahn, MD

Greg Barsh, MD, PhD

Suephy Chen, MD, MS

Amy Paller, MD

Christopher Sloey

Staff

Michael Hund  
Executive Director

Stephanie Ishoo  
Development Manager

Michelle Hall  
Senior Accountant

Curt Sharp  
Controller